AT BERKELEY MCB FALL 1999 Newsletter for Members and Alumni of the Department of Molecular & Cell Biology at the University of California, Berkeley

Home , Randy Schekman

Renovation of Barker Hall Begins

by Anita Joplin, Manager of Facilities, MCB Department

A renovation and seismic retrofit of Barker Hall is scheduled to begin in January, 2000. The retrofit will upgrade the building’s predicted seismic performance, rated in a campus survey as “poor,” to a rating of “good.” The renovation of Barker, which was built in 1964, will include moderniza- tion of major building support systems. Planned major building systems reno- vations and other improvements include piping, ventilation, elevators, constant tem- perature rooms, shared core equipment and The architect’s drawing of Barker Hall after renovation shows minor changes to its exterior belying the facilities, and new flooring, ceilings, and extensive improvements to its structure and support systems. conference rooms. A high-speed data net- work and an air conditioning system will The seismic retrofit will include new The scope of the seismic and systems also be installed. exterior shear walls and 50 steel-reinforced renovation will make it impossible for piers which will extend 60-feet deep to research, teaching, and administrative sup- support the new foundation. Large sections port programs to continue in Barker during MCB at Berkeley is a publication of of interior perimeter walls will be removed construction. Laboratories are moving to oth- the Department of Molecular and Cell Biology to install approximately 385 steel beams er MCB buildings (LSA and Stanley Hall) at the University of California, Berkeley. that will reinforce concrete support and to other biology buildings on campus DESIGN: Betsy Joyce columns. A new covered walkway, lobby, (Mulford, Valley Life Sciences, Wellman EDITOR: Laura Williams and exterior landscaping are also included Court). Laboratories are also moving to off-

SEND COMMENTS TO THE EDITOR: in the project. campus sites (Lawrence Berkeley National MCB Newsletter Funding for the retrofit, approximately Laboratory, Children’s Hospital Oakland University of California at Berkeley $14 million, was provided by Proposition Research Institute). Laboratories hope to Department of Molecular and Cell Biology 1A, the public education facilities bond return to the building late in 2001. 142 Life Sciences Addition #3200 that was passed by California voters in The renovation of Barker continues the Berkeley, CA 94720-3200 1998. The remainder of the funding will be campus construction of state-of-the-art OR E-MAIL: [email protected] from various campus sources and the biology facilities that began in the mid-1980’s Howard Hughes Medical Institute. In total, and will continue well into the next decade Current and past issues of the newsletter about $20 million has been allocated to the as part of the Health Sciences Initiative. (For are available on the MCB web site project, and additional funds have been more on the Health Sciences Initiative, see (mcb.berkeley.edu/news/newsletter.html). requested to complete the planned renova- page 4.) tions. Mark Schlissel

Schubert Family Associate Professor NEW FACULTY of Immunology

In July of 1999, immunologist Mark Currently, my lab is What is the most rewarding Education: Schlissel moved his laboratory from attempting to understand the achievement in your career • A.B. in Biochemical Sciences, the Johns Hopkins University School biochemistry and developmental so far? 1979, Princeton University. of Medicine where he had been an regulation of V(D)J recombina- Two of them come to mind. The • M.D. and Ph.D., 1986, Johns associate professor in the Departments tion. In particular, we have first is that I devised several novel Hopkins University, Thesis of Medicine, Molecular Biology and found that chromatin structure assays of gene rearrangement Advisor: Donald D. Brown. Genetics, and Oncology. He began his regulates the choice of gene seg- which have led to major break- Dissertation title: “The career at Johns Hopkins as an ments which undergo recombi- throughs in our understanding Developmental Regulation of MD/PhD student, continued as a nation and that transcriptional of the regulation of V(D)J recom- 5S RNA Gene Transcription medical resident, and later joined the activation of unrearranged gene bination. These assays are used in Xenopus laevis.” faculty as an assistant professor in segments precedes their activa- routinely in most every lab that • Medical Residency, 1986- 1991. He became an associate profes- tion for recombination. We are studies this process. Second, I 1988, The Johns Hopkins sor in 1995. currently studying the role of have gained great satisfaction Hospital. In fact, he left Johns Hopkins transcriptional enhancers in tar- from having run the basic • Postdoctoral Research, 1988- only for his postdoctoral research, geting the recombinase, the role immunology course for first year 1991, Whitehead Institute for which he conducted at the Whitehead of Ig protein as a regulator of B medical students at Hopkins. It Biological Research, Bristol- Institute for Biological Research at the cell development, and the regu- is difficult to teach basic science Myers Cancer Research Massachusetts Institute of Technology. lation of recombinase gene to medical students because many Fellowship, Advisor: David There, as a postdoctoral fellow in expression. of them do not realize how Baltimore. David Baltimore’s laboratory, Schlissel important it is for their under- began the study of the basic immuno- What is the significance of standing and treatment of disease. Selected Awards and Honors: logical process of antigen receptor gene your research? Two years after I took over the • Cancer Research Institute assembly which he continues today. The significance of this work lies poorly organized and unpopular Investigator Award, 1992. in the involvement of V(D)J course, it was the highest rated • Culpeper Foundation Scholar, Please describe your research. recombination in several disease course at Hopkins Medical 1993. We are interested in understanding processes. Mutations that dis- School. • Leukemia Society Scholar, how the process of antigen receptor rupt this process result in pro- 1996. gene assembly is regulated during found, inherited immunodefi- What special contribution • W.W. Smith Foundation lymphocyte development. Lympho- ciency—much more lethal than do you hope to make to the Scholar, 1997. cytes can recognize an enormous AIDS. Second, errors in the department? • American Society for Clinical array of foreign antigens. This selection of genes for recombina- I hope to bring the perspectives I Investigation, Elected to recognition is mediated by antigen tion can result in the activation gained while studying medicine Membership, (1998). receptors called immunoglobulin of oncogenes by translocation to and disease biology to the intel- • Graduate Student Teaching (Ig) on the surface of B cells and T Ig or TCR loci—a very common lectual community here. I also Award (1998). cell receptor (TCR) on the surface cause of leukemias and lym- hope to contribute to communal of T cells. Unlike any other meta- phomas. Finally, the regulation progress on an area of interest to a Personal Information: zoan genes, Ig and TCR genes are of the V(D)J recombination significant subset of the faculty I am married and have four assembled from gene-segments dur- reaction plays a role in self-toler- here—how the packaging of children. My wife, Monica ing lymphocyte development via a ance. If a randomly generated Ig DNA into chromatin influences Schwebs, is an environmental series of site-specific DNA recombi- gene produces an Ig with self- the activity of protein complexes lawyer. Our children are 14, 12, nation reactions called V(D)J specificity, the recombination which have to act upon DNA 9, and 6 years old. recombination. By this process, an reaction resumes and gets rid of substrates. Finally, I want to offer enormous diversity of antigen the offending gene. Failure of undergraduate and graduate stu- receptor structures, each specific for this process may contribute to dents good teaching and mentor- a particular antigen, are created autoimmune diseases such as ing. from a modest number of gene seg- lupus or rheumatoid arthritis. ments.

2 FACULTY NEWS

PROMOTIONS AND AWARDS AND HONORS

APPOINTMENTS RECEIVED FROM DECEMBER, 1998 THROUGH NOVEMBER, 1999

EFFECTIVE JULY 1, 1999 Robert Tjian received the Dan Koshland was named to Paola Timiras delivered the prestigious Alfred P. Sloan the Council on Bioscience by keynote addresses at the meet- Steve Martin was appointed Prize from the General Motors Governor Gray Davis. ing of the Chinese Physio- Cell and Developmental Cancer Research Foundation Edward Penhoet was named logical Society on August 15, Biology Division Head. and the Louisa Gross Horwitz to the Council on Bioscience 1999, and at the Graduation of Jeff Owen was appointed Prize from the Trustees of by Governor Gray Davis. the Master Gerontologia Neurobiology Division Columbia University, both Randy Schekman received the Social, University of Barcelona, Head. for 1999. 1999 Amgen Lecture Award Spain, on October 17, 1999. Caroline Kane was promoted of the Protein Society. Fred Wilt was “Scientist-in- to Adjunct Professor of Biochemistry and Molecular Jeremy Thorner was elected a Residence” at the San Biochemistry and Molecular Biology Faculty Fellow of the American Francisco Exploratorium for Biology. Mark Alper, Adjunct Professor, Academy of Microbiology Fall, 1999. Joshua Kaplan was promoted received the Lawrence Berkeley and was reappointed to the to Associate Professor of Cell National Laboratory William V. Power Chair in Genetics and Development and Developmental Biology. Outstanding Performance Biology for another 5-year Faculty Astar Winoto was promoted Award in September, 1999. term. Michael Levine is Guest to Professor of Immunology. Sharon Amacher was appoint- Professor of Zoology, David Presti was appointed ed to the Class of 1943 Cell and Developmental Universitat Zurich, for Senior Lecturer of Memorial Chair beginning Biology Faculty 1999/2000 and will be the Neurobiology with Security July 1, 1999. Beth Burnside received the Harvey Lecturer at Rockefeller of Employment (effective James Berger received a Outstanding Alumna Award University in 2000. January 1, 2000). Packard Fellowship for Science from the Graduate School of Jasper Rine received an NIH and Engineering and a UC the University of Texas at Merit Award and gave a Berkeley Faculty Fund for the Austin in May, 1999. keynote address at the National OBITUARY Biological Sciences Award, John Forte was appointed the Cancer Institute retreat. both for 1999. 1998 National Lecturer in MCB Professor emeritus Richard Calendar was elected a Physiology by the Swedish Immunology Faculty Heinz Fraenkel-Conrat died Councilor of the American Royal Academy of Sciences David Raulet was appointed to on April 10, 1999. He was Society for Virology. and was elected an Honorary the Choh-Hao Li Endowed 88. Fraenkel-Conrat was a Nicholas Cozzarelli was Member of the British Society Chair and was elected to the member of the National appointed a member of the of Gastroenterology. Program Committee of the Academy of Sciences and a Harvard Medical School Rebecca Heald received the American Association of recipient of the Lasker visiting committee. Pew Scholars Trust Award in Immunologists, both in July, Award, among other honors. Alexander Glazer was elected a Biomedical Sciences begin- 1999. With colleague Robley Fellow of the California ning July 1, 1999. Williams in 1955, Fraenkel- Academy of Sciences. Tito Serafini received the Neurobiology Faculty Conrat demonstrated that Jack Kirsch was the 1999 EJLB Foundation Scholar Corey Goodman was elected to infectious tobacco mosaic Aspirin Prize Lecturer at the Research Award and a UC the American Philosophical virus could be reconstituted Institut Quimic di Sarria, Berkeley Faculty Fund for the Society. from RNA and the protein Spain, and was appointed the Biological Sciences Award for Ehud Isacoff is part of a team coat, the first known exam- Chair of the U.S. Delegation 1999. of UCB researchers who ple of self-assembly of an to the 18th International Richard Steinhardt gave the received a 1999 David and active biological structure. Congress and General plenary address to the British Lucile Packard Foundation That same experiment Assembly of the IUBMB in Society Meeting for Cell Interdisciplinary Science proved that the genetic 2000 and the Chair of the Biology on September 20, Research Award. information was contained Nominating Committee of the 1999. Carla Shatz was elected to the in the RNA and not in the American Society for Richard Strohman received Institute of Medicine of the protein. Biochemistry and Molecular the Harris Award Lectureship National Academy of Sciences. Biology for 1999/2000. for the year 2000 at the University of Nebraska. 3 UPDATES New Cancer Therapy from Allison

The Center for Neuroscience has a new name and a new director. It has been re-named the A promising cancer treatment headed for Helen Wills Neuroscience Center in honor of the tennis star and Cal alumna who donated human trials was developed in the labora- her entire estate to the Center. The Center’s new director is MCB Neurobiology Professor tory of MCB Professor of Immunology Corey Goodman who has taken over for Carla Shatz. Shatz, MCB professor of neurobiology, James Allison. Their research on the is leaving UC Berkeley in June, 2000. For more on the Center, see the Spring, 1998 issue of basic mechanisms of T cell activation led the MCB Newsletter (mcb.berkeley.edu/news/spring98.html). directly to an immune therapy called CTLA-4 blockade. This therapy generally enhances immune responses so that they Biological Sciences are effective against tumors. “I consider myself a basic scientist . . . I do not necessarily look for ways to do tumor immunology,” said Allison. “But Engineering Physical Sciences once we find something that looks like it Health might be a fundamental way of regulating immune responses, then I immediately Sciences start thinking of some way to manipulate Initiative that . . . The translation can be pretty direct from basic work to the clinic.” Over many years, Allison’s lab and Public Health Berkeley Lab others have elucidated the interaction of signaling pathways involved in T cell activation, which Allison explains using an analogy. He likens the antigen receptor on The Wills Neuroscience Center is part of the Health Sciences Initiative, a multidiscipli- T cells to the ignition switch in a car and nary research and teaching program which was described in detail in the Spring, 1999 issue the antigen to the ignition key. “Each of (mcb.berkeley.edu/news/newsletter.html). the about 10 billion different ones circu- On October 6, 1999, UC Berkeley formally announced the plans for the Health lating in your body fit a different antigen Sciences Initiative. At the press conference, UC Berkeley Chancellor Robert Berdahl said, exactly,” explained Allison. “But there are “The development of knowledge today, especially in the health sciences, is occurring not pri- two additional types of signals. The co- marily within a particular discipline or field but at the intersection of many fields. To do the stimulatory signal, which is given by the kinds of health science that the twenty-first century will demand, to treat Alzheimer’s or bat- receptor called CD28, is like the gas pedal tle cancer or eliminate infectious diseases, to name only a few of challenges that the Health in your car. Just as turning the ignition on Sciences Initiative will undertake, will require cell biologists working with engineers working is not going to make the car move, the T with physicists working with public health experts.” cell is not activated without this second Berdahl estimated the total investment in the initiative at $500 million. Of that amount, signal.” He continued, “And then a cou- $300 million will be for new facilities that will replace Stanley Hall and Warren Hall, both ple of years ago, we demonstrated there is seismically poor buildings. another signal which is inhibitory, medi- The two new buildings will house as many as 400 UC Berkeley researchers brought ated by the receptor called CTLA-4, from various disciplines including biology, public health, chemistry, physics, engineering, and which is sort of like the brakes on a car. It psychology. About a dozen new faculty hires will join them, said Provost and Executive Vice down-regulates the immune system.” Chancellor Carol Christ. Allison thinks that the inhibition of Funding will be from a combination of public and private support. Along with T cell activation mediated by CTLA-4 is $24 million in state support, $100 million in private gifts has been collected. This includes one way our bodies keep autoimmune $50 million from an anonymous donor, which is the largest single gift ever to the UC reactions in check. But by protecting nor- Berkeley campus. mal cells from attack by T cells, it also Playing an important part in the Health Sciences Initiative will be MCB researchers, protects tumor cells. “In general we can’t whose work has already had a “very high impact on the field of biomedicine,” according to launch an immune response against can- MCB Co-Chair Jim Allison. Allison, who was one of three UC Berkeley faculty to speak at cer, the cancer is ourselves,” said Eric the press conference, said, “I think it is fair to say that Berkeley has a superb reputation for Small, an associate professor of urology at the quality of basic research in biology, but overall the contributions that work has made to UC San Francisco, in a UC Berkeley press health issues is perhaps underrecognized.” He went on to describe recent work from his lab release. “But Allison’s work shows that the as an example of basic research with medical applications. An account of his research follows on this page. 4 Lab RESEARCH HIGHLIGHTS

body does have the capacity to do so, and his “I don’t really have any hope that this therapy makes this more robust.” Small plans to is a magic bullet, that CTLA-4 blockade is direct the first clinical trials of the drug in going to take care of huge tumors,” said patients with prostate cancer. Allison. “But if the tumor’s size can be The drug is an antibody to the CTLA-4 reduced to something that the immune sys- receptor which blocks the receptor’s inhibitory tem can handle, hopefully, it can mop up and effects. “Blocking the CTLA-4 signal essentially also provide long-lasting immunity to recur- takes the brakes off the immune system at least rence . . . Metastasis is usually what kills temporarily, augmenting significantly the patients, and it ought to be able to take care immune responses,” said Allison. “We found of that.” that after merely injecting mice with this anti- In mice, Allison’s lab combined CTLA-4 body, T cells begin to come out of blood vessels, blockade with another immune therapy, a Jim Allison holds one of the mice that was cured of move into the tumor and begin to kill tumor tumor cell vaccine producing the cytokine melanoma. He said the mice they cured were given GM-CSF. Neither treatment works alone, cells.” a new treatment to stimulate the immune system. Simple administration of the antibody but together they synergize and cure a “nasty” (Photo by Herman Bustamante, Jr. Reprinted by type of melanoma that, Allison said, “no one resulted in rejection of tumors in a variety of permission of Contra Costa Times.) mouse tumor systems including colon and has been able to cure before.” prostate carcinomas. It was also effective against Because CTLA-4 blockade therapy metastases, the secondary growths that have maceutical company GenPharm, in Palo exploits such a basic mechanism of the spread from the primary tumor to other parts of Alto, CA. GenPharm has developed a tech- immune system, it may be useful not only for the body. nology for making completely human anti- treating cancer, but for other diseases as well. With this therapy, tumors are destroyed by bodies by immunizing genetically modified “If it works it could be generally applicable to the unleashing of an autoimmune attack, so it mice whose immunoglobulin genes have a lot of different things where you want a follows that normal tissue might also be affected. been replaced with human immunoglobulin stronger immune response,” said Allison. For For example, in melanoma model systems, the genes. GenPharm is a subsidiary of Medarex, instance, CTLA-4 blockade enhances the mice developed an autoimmune condition Inc., of Annandale, NJ, which has subli- effectiveness of vaccines. Allison believes it called vitiligo. Vitiligo is characterized by areas censed the patents for CTLA-4 blockade could accelerate the development of infec- of depigmentation of skin and hair caused by obtained by Allison and UC Berkeley. tious disease vaccines needed for antibiotic- destruction of melanocytes, the pigment- “Our target is to get this drug into resistant strains of bacteria such as those that producing cells from which melanoma arises. patients in the year 2000,” said Nils Lonberg, cause tuberculosis and for viruses such as The depigmentation is evident as white spots vice-president and director of research at HIV. He has experiments underway to apply on dark-colored mice, as shown in the photo GenPharm. “With a cancer treatment, you CTLA-4 blockade to an HIV vaccine model. above. Similarly, people who recover from never know until you put it into clinical tri- But taking on HIV and cancer is not melanoma often develop vitiligo. als, but the animal studies done by Allison's enough for Allison, he also plans to tackle “But those are the only ill effects that we lab are extraordinary. A lot of people have autoimmune disease. “Now the trick is to have seen, tissue-specific immunity to the tissue cured cancers in mice, but these studies really get back to lab and figure out how to make from which the tumor derived, which is certain- stand out amongst all the drugs that have it work in reverse. What we’re doing now is ly acceptable for many kinds of cancer,” said looked promising in mice. I think this may blocking the (inhibitory) signal, and what Allison, referring to cancers of the prostate, be an unusual opportunity to develop a we have got to figure out is how to give breast, and other non-vital tissues. “At this point drug that is also going to be spectacular in the signal. Then we can presumably turn we would not even propose this as therapy in humans, but we have to wait and see.” immune responses off,” said Allison. “That humans for (cancers of) tissues that are not dis- The initial trials will be designed to has implications for diabetes, multiple pensable, such as lung cancer.” assess safety, but clinical effects may be seen sclerosis, and other autoimmune diseases.” The cost of treatment with CTLA-4 block- because the trials will involve prostate cancer ade may be an autoimmune condition, but its patients and not healthy volunteers. benefits are considerable. “The beauty of elimi- Subsequent trials will prove whether CTLA-4 REFERENCES: blockade is an effective cancer treatment by Dana R. Leach, Matthew F. Krummel, and James P. Allison nating a tumor this way is that then the T cells (1996) Science 271: 1734-1736. ought to be able to go out and find metastases, itself or in combination with other therapies. Eugene D. Kwon, Arthur A. Hurwitz, Barbara A. Foster, and it provides immunity which, by definition, Allison suggests it could be useful in combi- Christopher Madias, Andrew L. Feldhaus, Norman means it should be a long-term cure and protec- nation with conventional chemotherapy (at M. Greenberg, Maurice B. Burg, and James P. Allison tion against recurrence,” said Allison. reduced dosages to limit side effects) or with (1997) Proc. Natl. Acad. Sci. U.S.A. 94: 8099-8103. In the last year, human antibodies to surgery or radiation, especially for large or Andrea van Elsas, Arthur A. Hurwitz, and James P. Allison (1999) J. Exp. Med. 190(3): 355-366. human CTLA-4 were produced by the biophar- resistant tumors.

5 CAREERS FOR PhDS

Graduate Students Create Course

Two MCB graduate student “In the same way that the weekly research seminars “I was familiar with only two career paths, volunteers, Jill Fuss and make students aware of exciting new fields of one was working as a postdoc until landing on the Jonghui Lee, created a career research, I felt that the department needed a career academic tenure track and the other was becoming seminar series entitled Life seminar series to insure that students know about a researcher in a biotech company.” After Grad School: Careers for different career options.” Bioscience PhDs, which was offered last Spring semester as Advice for Graduate Students MCB 294. They each came Life After Grad School: Careers for by Jonghui Lee, MCB Graduate Student up with the idea for such a Bioscience PhDs course independently and by Jill Fuss, MCB Graduate Student I urge fellow graduate students to find out what worked together to organize they can and want to do with their scientific it. Fuss obtained department MCB 294 was organized as a weekly seminar training and to become active in developing approval for the course with series, and, over the course of the semester, there skills for their desired careers, whatever those the help of faculty sponsor were presentations on sixteen different career may be. On campus, both the Career Center Caroline Kane. Fuss also options for bioscience PhDs. The topics ranged (career.berkeley.edu) and the Postdoctoral received a course development from more traditional careers, such as those in Association (www.berkeley.edu:5060) offer grant from campus. Lee academia and the biotechnology and pharmaceu- several workshops to help young scientists with almost single-handedly enlist- tical industries, to careers in forensic science, career planning and development for both aca- ed the approximately 40 patent law, finance, and science journalism. demic and non-academic careers. For those speakers, although she credits Every week, three or four speakers from a partic- who want to meet professionals with science others for suggesting the ular field were each given fifteen minutes to dis- backgrounds who are working in diverse fields, speakers, especially Ed cuss their careers, with plenty of time for ques- attending national meetings such as those orga- Penhoet, dean of the School tions afterward. The speakers were also available nized by the American Association for the of Public Health and co- for informal questions and discussion at a recep- Advancement of Science (www.aaas.org) and founder of Chiron Corpor- tion following the presentations. Each class was the Biotechnology Industry Organization ation, and Louise Rosenbaum, organized by a student host who also arranged a (www.bio.org) provide excellent opportunities. former associate director of dinner with the speakers and interested students. Various local professional groups such as the the UC Systemwide Biotech- The final presentation of the semester was by East Bay Chapter of the Association for nology Research and Edu- Andrew Green, PhD Counselor at the Career Women in Science (www.ebawis.org) and the cation Program. Lee and Fuss Center, who gave an overview of career resources Northern California Pharmaceutical Discussion also got assistance from the for graduate students, as well as advice on Group (www.ncpdg.org) also offer useful work- MCB Graduate Affairs Office. resumes, interviewing, and networking. shops and seminars throughout the year. The funding for the series The response to the course was overwhelm- From my involvement in MCB 294, I was provided by the MCB ingly positive. Every seminar was well attended, developed important organizational and per- Department along with a drawing between 40 and 110 people, mostly sonal skills and interacted with professionals in contribution from the UC graduate students. One student said that the many fields. I encourage others to take advan- Berkeley Career Center. Fuss’ course “opened up my eyes and mind in terms of tage of this valuable opportunity by getting description of the course and job opportunity.” Another commented, “Prior to involved in the organization of future MCB Lee’s advice for fellow gradu- this, I had very limited exposure to non-academic 295 series. (Contact Eileen Bell in the MCB ate students follow. job options and no idea where to look (for more Graduate Affairs Office.) information).” The popularity of the series sent a clear message that there is a real need for this EDITOR’S NOTE: Many of the speakers in this course, type of information. In response to this need, the including myself, were former MCB graduate students. department will offer this course every Spring If you would like to participate, please contact Eileen semester as MCB 295: Careers for Life Sciences Bell (510-642-0944, [email protected]). PhDs. 6 ALUMNI NEWS

MCB is tracking the employment status of its former graduate students and those from its Analysis of Graduate Employment Status predecessor departments. During last spring 80 and summer, Peggy McCutcheon-Smith, administrative assistant to MCB Co-Chair 70 Randy Schekman, verified the employment status of most of 415 graduates who received 60 their degrees from 1989, the year MCB was formed, to 1998, inclusive. For analysis, the 50 graduates were divided into the following Post-Doc five job categories: post-doc; academic 40 Academic (includes university and college professors, Biotech 30 research institute scientists, community col- Other lege instructors, and high school teachers); 20 Uncertain biotech (those employed in the biotechnology industry); other employment (e.g., 10 medicine, patent law, science writing, and in Each Category% of Graduates computer analysis/bioinformatics); and 0 uncertain (those we were unable to contact, 89 & 90 91 & 92 93 & 94 95 & 96 97 & 98 those between jobs). For graphing, the degree Cohorts by Year of Graduation (in two-year periods) years were combined into two-year periods.

Alumni Survey

We plan to include a regular feature on alumni news, and we would like to hear from you. Please complete the following for inclusion in an upcoming issue and mail to: University of California at Berkeley You may also submit the Department of Molecular and Cell Biology information via e-mail to: 597 Life Sciences Addition #3200 [email protected] Berkeley, CA 94720-3200

Name ______Degree(s) conferred and year ______

Address ______City/State/Zip______

E-mail address ______

BRIEF CAREER HISTORY: Title Name of Institution/Company Years ______

Any additional professional information or news about yourself or other alumni: ______

7 1998-99

PhD GRADUATES Francesca Mariani (Harland) Identification of Pakming Lau (Bentley) Induction of Filopodia New Molecules With Neuralizing Activities: by Direct Local Elevation of Intracellular Fall, 1998 XBF-2, Xenopus Brain Factor 2. Calcium Ion Concentration. Monique Nicoll (Meyer) Transcriptional and Greg Lazar (Handel) Hydrophobic Core So-ching Wong Brazer (Cande) Kinesin Motor Post-Transcriptional Regulation of xol-1 by the Packing and Protein Design. Proteins in Schizosaccharomyces pombe. Primary Sex Determination Signal in C. elegans. Jason Dillon Lieb (Meyer) Dosage Daniel Campbell (Shastri) Bacterial T Cell Sara Mieko Okamura (Rine) Genes Required Compensation and its Relationship to Antigens: Identification and Processing in the a/α Cell Type of Saccharomyces cerevisiae. Chromosome Segregation in C. elegans. Pathways. Sophie Petersen (Goodman) A Genetic Manuel Llinás (Marqusee) Investigation of the Ilil Carmi (Meyer) The Primary Sex Analysis of Synaptic Plasticity at the Role of Subdomains in Protein Folding and Determination Signal of Caenorhabditis elegans. Neuromuscular Junction in Drosophila. Misfolding. Mark Coles (Raulet) Role of the Major Michelle Poirier (Bennett) Biochemical Chad Paavola (Handel) Structure/Function Histocompatibility Complex and the Thymus Characterization and Structural Analysis of the Relationships in Monocyte Chemotactic in the Development of T Cells that Express Synaptic SNARE Complex. Protein-1. Natural Killer Cell Markers. Erica Roulier (Beckendorf) Tec29 Tyrosine Pedro Eslopor Paz (Shastri) Antigenic Peptides José De Jesus-Escobar (Harland) Analysis of Kinase: Multiple Function in the Development Presented by MHC-I Undergo Intermediate Noggin Function Using Monoclonal of Drosophila melanogaster. Processing Steps in the Cytosol and the Antibodies. Nam Vo (Chamberlin) In vitro studies of the Endoplasmic Reticulum. Heather Corbett Etchevers (Bentley) Neural Transcript Initiation Process by E. coli RNA Beatriz Quiñones (Bennett) Expression Crest-Related Differentiation of the Embryonic Polymerase. Patterns, Biochemical Properties, and Avian Brain. Frederick Wolf (Garriga) Posterior Migration Intracellular Localizations of the Syntaxin 2 Kathi Glauner (Isacoff) Structural and Guidance in Caenorhabditis elegans. Variants. Conformational Mapping of the Shaker Tanya Marie Raschke (Marqusee) Folding of Potassium Channel. Spring, 1999 Ribonuclease H from Escherichia coli: The Role Chau Huynh (Thorner) Molecular Genetic Joanne Adamkewicz (Thorner) Biochemical of a Partially Folded, Kinetic Intermediate. Analysis of a Phosphoinositide-specific and Genetic Analysis of MOT1, a Regulator of Kaye Reiter (Calendar) Studies of the Regulation Phospholipase C (PLC1 Gene Product) in the of the sid Promoter from Bacteriophage P4. Yeast Saccharomyces cerevisiae. Basal Transcription in Saccharomyces cerevisiae. Thomas Schlumpberger (Zucker) Adam Jacobs (Werblin) Patterns of Activity in Giselle Giorgi (Machen) Wound Healing and Tight Junction Dynamics in an Epithelial Computational Modeling of Calcium Action in the Vertebrate Retina: Prediction by a Synaptic Facilitation. Computational Model and Subsequent Monolayer and pH of the TGN. Victoria Allen Sharma (Alber) Novel Design of Physiological Confirmation of a Novel Seth Harris (Botchan) 2.1 Å Crystal Structure of the Human Papillomavirus Type 18 E2 Complementary Coiled-coil Peptides for the Mechanism for Edge Extraction in the Retina. Tumor Suppressor Protein, APC. Nikolas Jones (Beckendorf) Genetic Control of Activation Domain. David Speca (Ngai) Functional Identification of Salivary Duct Development in Drosophila Kristin Hendricks (Thorner) The FRQ1 Gene Product is a Positive Regulator of a Goldfish Odorant Receptor. melanogaster. Phosphatidylinositol 4-Kinase in the Yeast Zlatko Todorow (Schekman) Intracellular Edward Lein (Shatz) The Role of Neuro- Trafficking of Two S. cerevisiae Manno- trophins in the Activity-Dependent Formation Saccharomyces cerevisiae. syltranferase Complexes. of Patterned Neuronal Connections in the Louis Hom (Volkman) Activation of V-CATH, Mammalian Visual System. a Cysteine Protease Encoded by the Baculovirus Ying Li (Linn) I. Identification, Cloning and AcMNPV. Please note that Judith Davie, Jason Dugas, Characterization of three Associated Subunits Camillan Ling Huang (Winer) Cortical Projections and GABAergic Organization of the Andrew Kasarskis, and Nell Shimasaki are 1998-99 of HeLa polE; II. Responses of Pyridine graduates who were mistakenly included in the Nucleotide Metabolism to H O Challenge in Cat Medial Geniculate Body. 2 2 previous year’s list. E. coli. William Jackson (Martin) Transcriptional Regulation of the cdc18+ Gene of Schizosaccharomyces pombe.

University of California at Berkeley Non-profit Org. Department of Molecular and Cell Biology U.S. Postage PAID 597 Life Sciences Addition #3200 University of California Berkeley, CA 94720-3200

ADDRESS SERVICE REQUESTED